Photo by atikahakhtar from unsplash
CT-P13 and SB2 are two distinct biosimilars of the reference originator anti-tumour necrosis factor alpha monoclonal antibody infliximab. Real-life evidence has shown that the switch from infliximab originator to CT-P13… Click to show full abstract
CT-P13 and SB2 are two distinct biosimilars of the reference originator anti-tumour necrosis factor alpha monoclonal antibody infliximab. Real-life evidence has shown that the switch from infliximab originator to CT-P13 did not impair overall clinical efficacy and safety in patients with Crohn's disease, ulcerative colitis, spondyloarthritis, rheumatoid arthritis, psoriatic arthritis and chronic plaque psoriasis.
Keywords:
infliximab;
chronic plaque;
p13;
sb2;
plaque psoriasis;
infliximab biosimilar
Journal Title: British Journal of Dermatology
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: British Journal of Dermatology
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!